An Optimal Dose Finding Study of N-Acetylcysteine in Patients with Myeloproliferative Neoplasms

Recruiting

Phase 1

Phase 2

N-AcetylcysteineAn Optimal Dose Finding Study of N-Acetylcysteine in Patients with Myeloproliferative Neoplasms

Sponsor:

UCLA

Code:

NCT05123365

Conditions

Myeloproliferative Neoplasm

MPN

Essential Thrombocythemia

Polycythemia Vera

Myelofibrosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

N-Acetylcysteine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-09. This information was provided to ClinicalTrials.gov by University of California, Irvine on 2025-02-10.